 HOSTE D BY

Available online at [www.sciencedirect.com](http://www.sciencedirect.com/science/journal/2314808X)

**ScienceDirect**

journal homepage: [http://ees.elsevier.com/ejbas/default.asp](http://http//ees.elsevier.com/ejbas/default.asp)

**Full Length Article**

**Niacin improves adiponectin secretion, glucose tolerance and insulin sensitivity in diet-induced obese rats**



***Ayodele Olufemi Morakinyo*** [***a***](#_bookmark0)***,***[***\****](#_bookmark3)***, Titilola Aderonke Samuel*** [***b***](#_bookmark1)***,***

***Daniel Abiodun Adekunbi*** [***c***](#_bookmark2)***, Olufeyi Adefunke Adegoke*** [***a***](#_bookmark0)

a *Department of Physiology, College of Medicine of the University of Lagos, Idi-Araba 100254, Lagos, Nigeria*

b *Department of Biochemistry, College of Medicine of the University of Lagos, Idi-Araba 100254, Lagos, Nigeria*

c *Department of Physiology, Benjamin S. Carson (Snr.) School of Medicine, Babcock University, Ilishan-Remo, Nigeria*

A R T I C L E I N F O A B S T R A C T

*Article history:*

Received 1 June 2015

Received in revised form 20 August 2015

Accepted 21 August 2015

Available online 1 September 2015

*Keywords:*

Niacin

Glucose tolerance Insulin sensitivity Adiponectin Obesity

The present study examined the effect of dietary niacin supplementation on fat mass, glucose control, insulin sensitivity, lipid profile, and adiponectin level in diet-induced obese rats.

Male Sprague-Dawley rats (n = 21) were initially divided into 2 groups of seven and four-

teen rats; the group of 14 rats was fed with a high-fat diet (HFD) and the other group of 7 rats consumed the control diet. Eight weeks after the diet regimen started, half of the rats from the HFD group were shifted to the niacin-supplemented diet (HFND; 1 mg niacin/kg diet) while the remaining rats continued on the HFD for another 6 weeks. Results obtained showed that HFD-fed obese rats exhibited significant increase in body weight gain, reduced glucose tolerance, insulin sensitivity and increased adiposity, as well as altered lipid profile after 8 weeks of feeding compared with the controls. However, niacin-supplemented rats showed reduced weight gain and body weight compared with HFD-induced obese rats even in the absence of a significant difference in the food intake among the groups in the ex- periment. In addition, the rats showed an improved time-course glucose control and insulin sensitivity as demonstrated by a significantly lower area under curve (AUC) values for the glucose curves. The plasma levels of cholesterol, triglycerides and low density lipoprotein (LDL) returned towards control values in rats supplemented with niacin compared with obese rats. The findings suggest that niacin exerts beneficial effect on adiposity, glucose toler- ance and insulin sensitivity, and plasma lipids, and that it specifically modulates the level of serum adiponectin under obese condition.

© 2015 Mansoura University. Production and hosting by Elsevier B.V. This is an open

access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by->

nc-nd/4.0/).

\* *Corresponding author.* Tel.: +234 8055947623.

*E-mail addresses:* [morakinyofemi@yahoo.com](mailto:morakinyofemi@yahoo.com); [aomorakinyo@cmul.edu.ng](mailto:aomorakinyo@cmul.edu.ng) (A.O. Morakinyo). <http://dx.doi.org/10.1016/j.ejbas.2015.08.003>

2314-808X/© 2015 Mansoura University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/).](http://creativecommons.org/licenses/by-nc-nd/4.0/))

# Introduction

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1 – Composition of experimental diets (unit: g/Kg).** | | | |
| Components | Control | HFD | NSD |
| Corn flour | 529.5 | 330.5 | 329.5 |
| Casein | 200 | 200 | 200 |
| Sucrose | 100 | 100 | 100 |
| Soybean oil | 70 | 40 | 40 |
| Cellulose | 50 | 50 | 50 |
| Mineral mix | 35 | 35 | 35 |
| Vitamin mix | 10 | 10 | 10 |
| L-cystine | 3 | 3 | 3 |
| Choline | 2.5 | 2.5 | 2.5 |
| Butter | 0 | 229 | 229 |
| Niacin | 0 | 0 | 1 |
| Total | 1000 | 1000 | 1000 |

Obesity is characterized by excessive accumulation or in- crease in adipose tissue mass [[1]](#_bookmark9). The adipose tissue secretes numerous bioactive substances [[2]](#_bookmark10) collectively known as adipocytokines. Adiponectin is the most abundant of these adipocytokines and is known to have anti-inflammatory, anti- atherogenic and insulin-sensitizing properties [[3,4]](#_bookmark11). It modulates a number of metabolic processes, including glucose regula- tion and fatty acid oxidation [[5]](#_bookmark12), and plays an important role in the suppression of metabolic derangements that cause insulin resistance and type 2 diabetes mellitus (T2DM) [[6]](#_bookmark14).

Interestingly, although adiponectin is secreted by adipose tissue, the plasma level of adiponectin correlates inversely with adiposity and directly with insulin sensitivity [[7–10]](#_bookmark15). It has been found that the plasma level of adiponectin in obese individu- als was lower than in non-obese ones [[7]](#_bookmark15); furthermore, low adiponectin concentrations in the plasma correlate with T2DM [[11]](#_bookmark16). However, weight loss and some lipid-modifying drugs, such as omega-3 fatty acids, statins and niacin, are known to in- crease adiponectin concentration [[4,12]](#_bookmark13).

Niacin (also called nicotinic acid) is an old lipid-modifying drug that has favourable effects on all traditionally mea- sured lipid parameters [[13,14]](#_bookmark17). Niacin increases high density lipoprotein (HDL), but reduces low density lipoprotein (LDL), cholesterol (CHOL), and triglycerides (TRIG). Animal studies have shown that niacin stimulates adiponectin secretion in adipocytes [[15,16]](#_bookmark18). A single dose of niacin given orally or through intra-peritoneal injection acutely increases serum adiponectin concentrations in rats and mice within minutes, and this effect is dependent upon activation of the niacin receptor [[15]](#_bookmark18). Others have also demonstrated that niacin treatment results in in- creased adiponectin mRNA [[16,17]](#_bookmark19). Additionally, niacin enhanced PPAR*γ* in rabbit adipocytes [[18]](#_bookmark20); PPAR*γ* is a transcription factor that plays a central role in adipocyte biology, and it regulates adiponectin gene expression, processing, and secretion [[19]](#_bookmark21).

Given that niacin increases adiponectin level, it is conceiv-

able that niacin could improve insulin sensitivity; however, previous studies reported otherwise [[20–23]](#_bookmark22). For instance, Grundy et al. [[20]](#_bookmark22) suggested niacin may cause some negative effects on glucose and insulin metabolism by exacerbating glucose control and insulin sensitivity leading to hyper- glycaemia. Other studies have also demonstrated that treat- ment with niacin produced hyperglycaemia and insulin resistance [[24]](#_bookmark23). Meanwhile, past reports on the adverse effect of niacin on glucose and insulin sensitivity are limited with hyperlipidaemic or non-obese subjects. The present study was therefore carried out to investigate the effect of niacin on adi- posity, glucose tolerance, insulin sensitivity and adiponectin level in HFD-induced obese rats.

1. groups of seven and fourteen rats, housed in transparent plastic cages, in environmentally controlled room under stan- dard temperature (24 ± 2 0C) and humidity (45–64%), with alternating 12-h light–dark cycles. Generally, the study was con- ducted in accordance with the internationally accepted guidelines for laboratory animal use and care [[19]](#_bookmark21) and ap- proved by the Experimentation Ethics Committee on Animal Use of the College of Medicine of the University of Lagos (2014/ 08). The group of 14 rats was fed with a high-fat diet (HFD) and the group of 7 rats consumed the control diet. Eight weeks after the diet regimen started, half of the rats from the HFD group were shifted to the niacin-supplemented diet (NSD; 1 mg niacin/ kg diet) while the remaining rats continued on the HFD for another 6 weeks. Water and food were available *ad libitum* to the rats throughout the experimental period, and their diet intake and body weights were recorded weekly. The compo- sition of the experimental diets employed in this study is shown in [Table 1](#_bookmark4).

## *Oral glucose tolerance test*

Oral glucose tolerance test (OGTT) was performed at the end of the 14-week experimental period. For this purpose, the animals were fasted for about 16 h prior to the time the test commenced. Subsequently, a zero time (baseline) blood sample was drawn and designated 0 min glucose level. Thereafter, each rat was given an oral glucose load of 2g/kg BW [[20]](#_bookmark22) of glucose solution (D-Glucose: Sigma Cat. No. G-7528). Blood sample was drawn from tail vein after the glucose load at intervals of 30, 60, 120 and 180 min for measurement of glucose level. The glucose level was measured with a portable Acu-Chek glucose meter (Roche Diagnostics, Germany).

## *Insulin tolerance test*

Rats that were used for insulin tolerance test (ITT) were fasted

for 4 h. Basal blood glucose levels (0 min) were measured fol-

# Materials and methods

## *Animals, diet and experimental design*

The experiment was carried out with male Sprague-Dawley rats (n = 21) obtained from the Animal House of the College of Medi- cine, University of Lagos, Lagos, Nigeria. They were divided into

lowed by injection of insulin (0.5 U/kg BW; Human Insulatard, Novo Nordisk) into the peritoneum, and blood glucose levels were measured at 15, 30, 60, 120 and 180 min by portable glucose meter using tail vein blood. Total area under the curves (AUC) in response to glucose or insulin administration was calcu- lated using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, California USA.

## *Visceral fat*

Total visceral fat was measured as the sum of epididymal, omental and retroperitoneal fat deposits, and was used as an index of obesity in the animals. For this purpose, epididymal, omental and retroperitoneal fat pads were quickly excised from the animals at the time of their sacrifice for determining total visceral fat [[25]](#_bookmark24).

## *Biochemical analysis*

Serum concentrations of TRIG, CHOL, LDL and HDL were de- termined with an automatic blood chemical analyser (BT 2000 Plus, Germany). Insulin and adiponectin were assayed using the ELISA Kits (Elabscience, Wuhan, China) according to the manufacturer’s instruction. All the reagents and samples were stored at room temperature before conducting the experiment.

## *Statistical analysis*

Data are expressed as mean ± standard error of mean (SEM) and analysed using the ANOVA followed by SNK post-hoc test. A “*p*” value below 0.05 was considered to be statistically sig- nificant. All the analyses were carried out using the GraphPad Instat Version 3.05 for Window Vista, GraphPad Software, San Diego, California, USA.

# Results

## *Effects of niacin supplementation on food intake,* body weight and weight gain in obese rats

As indicated in [Table 2](#_bookmark5), there was no significant difference in the body weight among the groups at the commencement of the experiment. During the first 8 weeks of the experimental period, there was a significant (p < 0.01) increase in body weight of HFD-fed groups 176.29 ± 5.26 g and 166.4 ± 9.61 g (239.01% and 238.62% increase, respectively) compared with

131.14 ± 5.91 (157.13% increase) of the control group. Supple- mentation with niacin thereafter however attenuated the gain

in body weight (332.23% gain), which was notably less than

that of HFD only group (425.63% gain) rats at the end of the experiment. With a value of 212.4 ± 8 g at the end of the 14- week experimental period, the final body weight of the niacin- supplemented rats was significantly (p < 0.001) lower when compared with the HFD-induced obese rats (273.33 ± 4.47 g). Meanwhile, no significant difference was observed in the food intake among the groups at weeks 4, 8 and 14 of the experiment.

## *Effects of niacin supplementation on oral glucose* tolerance in obese rats

Niacin supplementation improved the glucose clearance in HFD- obese rats ([Fig. 1](#_bookmark6)). Before the glucose load, the blood glucose levels at 0 min were significantly different among groups. The glucose challenge of 2 g/kg dramatically raised the blood glucose level in all groups at 30 and peaked at 60 min. Only control rats had their blood glucose level returned to the baseline before 180 min while it remained above the baseline level in both HFD and niacin-supplemented groups. [Fig. 3](#_bookmark7) shows the area under curve for the OGTT (AUCGTT); compared with control rats, the

AUCGTT of the obese rats was significantly (p < 0.05) higher; however, niacin supplementation significantly (p < 0.05) reduced

the AUCGTT in the obese rats.

## *Effects of niacin supplementation on insulin* tolerance in obese rats

The effect of niacin supplementation on insulin tolerance in experimental rats is presented in [Fig. 2](#_bookmark6). After an intra-peritoneal injection of insulin, there was a significant decrease in the blood glucose levels of all groups. The blood glucose level of the control group decreased continuously, and the lowest level was attained at the 120 min time interval. However, obese rats and niacin-supplemented rats produced a lesser degree of fall in their blood glucose level as com- pared with the control group. This observation was reinforced

with the AUC data for ITT (AUCITT) shown in [Fig. 3](#_bookmark7). The AUCITT for the obese group of rats was significantly (p < 0.001) higher than the control rats; however, niacin-supplemented rats showed a significantly (p < 0.001) lower AUCITT compared with obese rats.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2 – Body weight, weight gain and food intake in control and experimental rats.** | | | | |
| Parameters | Timeline | Control | Obese | Obese + niacin |
| Body weight (g) | Baseline | 51.00 ± 1.32 | 52.00 ± 1.23 | 49.14 ± 1.53 |
|  | 4 weeks | 86.14 ± 4.72 | 115.88 ± 3.88\*\* | 111.42 ± 8.51\*\* |
|  | 8 weeks | 131.14 ± 5.91 | 176.29 ± 5.26\*\* | 166.4 ± 9.61\*\* |
|  | 14 weeks | 194.42 ± 4.64 | 273.33 ± 4.47\*\*\* | 212.4 ± 8.02### |
| Food intake (g) | Baseline | 62.57 ± 3.24 | 71.14 ± 1.86 | 72.14 ± 4.50 |
|  | 4 weeks | 90.71 ± 3.63 | 94.29 ± 2.10 | 96.57 ± 2.99 |
|  | 8 weeks | 100.43 ± 2.27 | 104.71 ± 2.76 | 107.57 ± 3.79 |
|  | 14 weeks | 122.86 ± 2.14 | 122.86 ± 2.64 | 128.43 ± 3.73 |
| % Weight gain | 4 weeks | 68.9 | 122.84 | 126.74 |
|  | 8 weeks | 157.13 | 239.01 | 238.62 |
|  | 14 weeks | 281.21 | 425.63 | 332.23 |
| Results are presented as mean ± SEM, n = 6. \*P < 0.05, \*\*P < 0.01 and \*\*\*P < 0.001 compared with control group; ###P < 0.001 compared with obese group. | | | | |

**Fig. 1 – Glucose response curves during oral-glucose-tolerance test in control and experimental rats. Each point represents** **the mean, n = 6.**

190

170

150

130

110

90

70

50

0

30

60

**Time (min)**

Obese

120

180

Control

Obese+Niacin

**Blood Glucose (mg/dl)**

## *Effects of niacin supplementation on visceral fat in* obese rats

There was a significant increase in the weight of epididymal (p < 0.05), omental (p < 0.01) and retroperitoneal (p < 0.05) fat pads in obese rats compared with the control. The weight of the omental fat pad was significantly lower (p < 0.01) in the niacin-supplemented group compared with the obese rats. However, there was no significant difference in the weight of the epididymal and retroperitoneal fat pads of niacin- supplemented rats when compared with their obese counterparts, although the niacin-supplemented values were marginally lower ([Table 3](#_bookmark7)).

**Blood Glucose (mg/dl)**

## *Effects of niacin supplementation on plasma lipid* profile in obese rats

The level of plasma CHOL in the obese group was signifi- cantly higher (p < 0.01) than control rats. However, niacin- supplemented rats showed a significant (p < 0.05) decrease in CHOL concentration compared with HFD-obese rats. Simi- larly, obese rats showed a significant (p < 0.05) increase in TRIG concentration, indicating hypertriglyceridemia as compared with normal rats. Supplementation with niacin however failed to attenuate the development of hypertriglyceridemia. HFD- fed obese rats showed a significant (p < 0.001) increase in LDL concentration compared with control rats; however, niacin

**Fig. 2 – Glucose response curves during insulin-tolerance test in control and experimental rats. Each point represents the mean, n = 6.**

160

140

120

100

80

60

40

20

0

0

15

30

60


120

180

**Time (min)**

Control Obese Obese+Niacin

**Fig. 3 – AUC for OGTT and ITT in control and experimental rats. Results are presented as mean ± SEM, n = 6. \*P < 0.05 compared with control group; #P < 0.05 compared with obese group.**



35000

30000

\*

25000

#

20000

\*\*\*

15000

10000

###

5000

0

GTT

Control

ITT

Obese

Obese+Niacin

**Area under the curve (mg/dl/min)**

supplementation reversed the adverse changes in LDL level. Plasma HDL concentration was significantly (p < 0.05) reduced in the HFD-fed obese rats as compared with control rats. Supple- mentation with niacin produced a significant (p < 0.001) increase in HDL concentration ([Fig. 4](#_bookmark8)).

## *Effects of niacin supplementation on serum insulin* and adiponectin levels in obese rats

HFD-fed obese rats showed a significant increase (p < 0.01) in the insulin concentration accompanied by a significant de- crease (p < 0.001) in adiponectin concentration compared with control rats. Supplementation with niacin reversed these re- sponses in obese rats. The level of serum insulin was significantly lower (p < 0.05) while adiponectin level was sig- nificantly higher (p < 0.01) in the niacin-supplemented group as compared to obese rats ([Table 4](#_bookmark8)).

# Discussion

The results of the present study demonstrate impaired meta- bolic processes, such as glucose intolerance, insulin insensitivity


and dyslipidemia in HFD-obese rats. Supplementation with niacin however significantly improved most of the above- stated metabolic deficits. Even though there was no sign of toxicity and food intake remained within the range of control values, supplementation with niacin attenuated weight gain in obese rats and visceral adiposity as a consequence of lowered fat accretion [[26]](#_bookmark25).

Many studies have demonstrated that obesity influences glucose metabolism, insulin sensitivity and inflammation [[26]](#_bookmark25), showing a link between increased adiposity and the develop- ment of diabetes mellitus. In the present study, supplementation with niacin modulates the apparent hyperglycaemia and glucose intolerance in HFD-obese rats [[27–29]](#_bookmark26). In contrast, some other studies have also reported a decrease in glucose with niacin therapy especially in a non-obese condition [[30,31]](#_bookmark28). Yang et al.

[[29]](#_bookmark27) have reported that niacin treatment has modest improve- ment on glucose control as it lowers the accumulative AUC during oral glucose tolerance test in a rodent model of obesity and type 2 diabetes. However, Li et al. [[32]](#_bookmark29) also found that nicotinamide-treated rats had impaired glucose tolerance and insulin sensitivity when compared with the control rats. The inconsistent results observed between studies with obese sub- jects and non-obese suggest that responses to niacin treatment may be dependent on specific pathophysiological conditions.

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 3 – Weight of epididymal, omental and retroperitoneal fat pads in control and experimental rats.** | | | |
| Parameters | Control | Obese | Obese + niacin |
| Epididymal fat pad (g) | 0.93 ± 0.04 | 1.15 ± 0.05\* | 1.01 ± 0.07 |
| Epididymal fat pad/body weight ratio | 0.48 | 0.38 | 0.48 |
| Omental fat pad (g) | 0.85 ± 0.06 | 1.18 ± 0.05\*\* | 0.95 ± 0.05## |
| Omental fat pad/body weight ratio | 0.44 | 0.4 | 0.46 |
| Retroperitoneal fat pad (g) | 0.98 ± 0.06 | 1.29 ± 0.09\* | 1.09 ± 0.09 |
| Retroperitoneal fat pad/body weight ratio | 0.5 | 0.47 | 0.51 |
| Results are presented as mean ± SEM, n = 6. \*P < 0.05 and \*\*P < 0.01 compared with control group; ##P < 0.01 compared with obese group. | | | |

**Fig. 4 – Plasma concentrations of CHOL, TRIG, HDL and LDL in control and experimental rats. Results are presented as mean ± SEM, n = 6. \*P < 0.05 compared with control group; #P < 0.05 compared with obese group.**



2.5

\*\*

2

#

1.5

\*

1

###

\*

\*\*\*

0.5

##

0

CHOL

TRIG

Obese

HDL

Obese+Niacin

LDL

Control

**Concentration (mmol/l)**

One of the underlying factors for glucose control is insulin, its level and sensitivity. In this study, niacin supplementa- tion also enhanced insulin sensitivity in obese rats. Increased glucose tolerance and reduction in the concentration of plasma insulin can be related to increased insulin sensitivity and lower degree of disorder of lipid metabolism [[33]](#_bookmark30). Excess blood lipid has serious impact on whole body metabolic function and pro- found negative effect on insulin signalling within the muscle tissue [[34]](#_bookmark31). Dyslipidemia, which is characterized by elevated TG, low HDL and increased LDL, usually precedes glucose in- tolerance and decrease insulin sensitivity through the inhibition of insulin-mediated glucose transporters in skeletal muscle and by contributing to hyperinsulinaemia [[35]](#_bookmark32). Controlling dyslipidemia by niacin in the present study therefore appears to be an attractive target for improving the aspect of meta- bolic deficits that result from deleterious hormonal effects of adipose tissues. An approach to restore insulin sensitivity is a critical focus to achieving glucose homeostasis under obese conditions.

Adiponectin is a novel adipocyte-specific protein that has been suggested to play a role in the development of insulin

this study, niacin supplementation significantly increased the level of serum adiponectin in HFD-induced obese rats. This sug- gests that the niacin-mediated improvements in glucose control and insulin sensitivity may in part be due to the alteration of adiponectin signalling. There is a consensus in literature that adiponectin generally exerts insulin sensitizing, anti- inflammatory and anti-apoptotic actions on a number of different cell types [[36]](#_bookmark33). Because a negative correlation exists between various hormones (including insulin) associated with insulin resistance and obesity on one hand, and adiponectin secretion on the other hand [[37]](#_bookmark34), niacin may indirectly mod- erate insulin secretion via its effect on adiponectin.

In conclusion, the present results suggest that niacin im- proves adiposity, lipid profile, insulin sensitivity, glucose tolerance and modulates adiponectin level in obese rats. More research is needed to determine the modulatory effects of niacin on adipokines as it greatly influences insulin sensitivity, glucose metabolism and inflammation, and may provide a molecular link between increased adiposity and glucose intolerance/ diabetes mellitus.

resistance and atherosclerosis. Furthermore, reduced expres-

sion of adiponectin has been associated with some degree of insulin resistance in animal studies, indicating a role for hypoadiponectinaemia in relation to insulin resistance [[36]](#_bookmark33). In

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 4 – Concentration of insulin and adiponectin in control and experimental rats.** | | | |
| Parameters | Control | Obese | Obese + niacin |
| Insulin (pmol/l) | 693 ± 35 | 1076 ± 98\*\* | 842 ± 64# |
| Adiponectin (ng/ml) | 986 ± 87 | 651 ± 58\*\*\* | 813 ± 72## |
| Results are presented as mean ± SEM, n = 6. \*P < 0.05, \*\*P < 0.01 and  \*\*\*P < 0.001 compared with control group; #P < 0.05 and ##P < 0.01 com-  pared with obese group. | | | |

# Acknowledgement

The authors wish to thank Sunday Ogunnowo who provided technical assistance during the experiments.

R E F E R E N C E S

1. [Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0010) [as endocrine organ and its role in obesity. Arch Med Res](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0010) [2008;39:715–28.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0010)
2. [Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin:](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0015) [more than just another fat cell hormone? Diabetes Care](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0015) [2003;26:2442–50.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0015)
3. [Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0020) [anti-atherogenic properties of adiponectin. Biochimie](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0020) [2012;94(10):2137–42.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0020)
4. [Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0025) [cardiovascular disease: response to therapeutic](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0025) [interventions. J Am Coll Cardiol 2007;49(5):531–8.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0025)
5. [Fagerberg B, Kellis D, Bergstrom G, Behre CJ. Adiponectin in](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0030) [relation to insulin sensitivity and insulin secretion in the](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0030) [development of type 2 diabetes: a prospective study in 64-](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0030) [year-old women. J Intern Med 2011;269:636–43.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0030)
6. [Sheng T, Yang K. Adiponectin and its association with](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0035) [insulin resistance and type 2 diabetes. J Genet Genomics](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0035) [2008;35:321–6.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0035)
7. [Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0040) [J, et al. Paradoxical decrease of an adipose-specific protein,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0040) [adiponectin, in obesity. Biochem Biophys Res Commun](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0040) [1999;257(1):79–83.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0040)
8. [Bambace C, Telesca M, Zoico E, Sepe A, Olioso D, Rossi A,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0045)

[et al. Adiponectin gene expression and adipocyte diameter:](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0045) [a comparison between epicardial and subcutaneous adipose](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0045) [tissue in men. Cardiovasc Pathol 2011;20(5):e153–6.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0045)

1. [Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0050) [effects of adiponectin: molecular mechanisms and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0050) [potential therapeutic intervention. Clin Sci (Lond)](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0050) [2008;114:361–74.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0050)
2. [Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0055) [Adiponectin and adiponectin receptors in insulin resistance,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0055) [diabetes, and the metabolic syndrome. J Clin Invest](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0055) [2006;116(7):1784–92.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0055)
3. [Han SH, Sakuma I, Shin EK, Koh KK. Anti-atherosclerotic and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0060) [anti-insulin resistance effects of adiponectin: basic and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0060) [clinical studies. Prog Cardiovasc Dis 2009;52:126–40.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0060)
4. [Wanders D, Plaisance EP, Judd RL. Pharmacological effects of](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0065) [lipid-lowering drugs on circulating adipokines. World J](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0065) [Diabetes 2010;1(4):116–28.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0065)
5. [Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0070) [fibrates in atherogenic dyslipidemia: pharmacotherapy to](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0070) [reduce cardiovascular risk. Pharmacol Ther 2010;126(3):314–](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0070) [45.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0070)
6. [Song WL, FitzGerald GA. Niacin, an old drug with a new](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0075) [twist. J Lipid Res 2013;54(10):2586–94.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0075)
7. [Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0080) [Judd RL. Niacin stimulates adiponectin secretion through](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0080) [the GPR109A receptor. Am J Physiol Endocrinol Metab](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0080) [2009;296(3):E549–58.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0080)
8. [Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0085) [RP. Anti-inflammatory effects of nicotinic acid in adipocytes](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0085) [demonstrated by suppression of fractalkine, RANTES, and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0085) [MCP-1 and up-regulation of adiponectin. Atherosclerosis](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0085) [2010;209(1):89–95.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0085)
9. [Linke A, Linke A, Sonnabend M, Fasshauer M, Höllriegel R,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0090)

[Schuler G, et al. Effects of extended-release niacin](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0090)

[on lipid profile and adipocyte biology in patients with](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0090) [impaired glucose tolerance. Atherosclerosis 2009;205:](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0090) [207–13.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0090)

1. [Zhao SP, Yang J, Li J, Dong SZ, Wu ZH. Effect of niacin on](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0095) [LXRalpha and PPARgamma expression and HDL-induced](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0095) [cholesterol efflux in adipocytes of hypercholesterolemic](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0095) [rabbits. Int J Cardiol 2008;124(2):172–8.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0095)
2. [Astapova O, Leff T. Adiponectin and PPARγ: cooperative and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0100)

[interdependent actions of two key regulators of metabolism.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0100) [Vitam Horm 2012;90:143–62.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0100)

1. [Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105) [Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105) [daily niacin for the treatment of dyslipidemia associated](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105) [with type 2 diabetes: results of the assessment of diabetes](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105) [control and evaluation of the efficacy of niaspan trial. Arch](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105) [Intern Med 2002;162(14):1568–76.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0105)
2. [Poynten AM, Gan SK, Kriketos AD, O’Sullivan A, Kelly JJ, Ellis](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0110) [BA, et al. Nicotinic acid-induced insulin resistance is](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0110) [related to increased circulating fatty acids and fat](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0110)

[oxidation but not muscle lipid content. Metabolism 2003;](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0110) [52(6):699–704.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0110)

1. [Koh Y, Bidstrup H, Nichols DL. Niacin increased glucose,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0115) [insulin, and C-peptide levels in sedentary non-diabetic](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0115) [postmenopausal women. Int J Womens Health 2014;6:913–](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0115) [20.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0115)
2. [Pieper JA. Overview of niacin formulations: differences in](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0120) [pharmacokinetics, efficacy, and safety. Am J Health Syst](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0120) [Pharm 2003;60:S9–14, quiz 25.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0120)
3. [Chen L, So WY, Li SY, Cheng Q, Boucher BJ, Leung PS.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0125) [Niacin-induced hyperglycemia is partially mediated via](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0125) [niacin receptor GPR109a in pancreatic islets. Mol Cell](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0125) [Endocrinol 2015;404:56–66.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0125)
4. [Kim YW, Kim JY, Lee SK. Surgical removal of visceral fat](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0130) [decreases plasma free fatty acid and increases insulin](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0130) [sensitivity on liver and peripheral tissue in monosodium-](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0130) [glutamate (MSG)-obese rats. J Korean Med Sci 1999;14:539–](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0130) [45.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0130)
5. [Wang W, Basinger A, Neese RA, Christiansen M, Hellerstein](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0135) [MK. Effects of nicotinic acid on fatty acid kinetics, fuel](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0135) [selection, and pathways of glucose production in women.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0135) [Am J Physiol Endocrinol Metab 2000;279(1):E50–9.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0135)
6. [Masoodi M, Kuda O, Rossmeisl M, Flachs P, Kopecky J. Lipid](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0140) [signaling in adipose tissue: connecting inflammation](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0140)

[and metabolism. Biochim Biophys Acta 2015;1851(4):](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0140) [503–18.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0140)

1. [Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145) [Egan D, et al. Effect of niacin on lipid and lipoprotein levels](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145) [and glycemic control in patients with diabetes and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145) [peripheral arterial disease: the ADMIT study: a randomized](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145) [trial. Arterial Disease Multiple Intervention Trial. JAMA](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145) [2000;284(10):1263–70.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0145)
2. [Yang SJ, Choi JM, Kim L, Park SE, Rhee EJ, Lee WY, et al.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0150) [Nicotinamide improves glucose metabolism and affects](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0150) [the hepatic NAD-sirtuin pathway in a rodent model of](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0150) [obesity and type 2 diabetes. J Nutr Biochem 2014;25(1):66–](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0150) [72.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0150)
3. [Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0155) [Kashyap M, et al. Equivalent efficacy of a time-release form](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0155) [of niacin (Niaspan) given once-a-night versus plain niacin in](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0155) [the management of hyperlipidemia. Metabolism](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0155) [1998;47(9):1097–104.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0155)
4. [Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0160) [Impaired beta-cell function in human aging: response to](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0160) [nicotinic acid-induced insulin resistance. J Clin Endocrinol](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0160) [Metab 2006;91(9):3303–9.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0160)
5. [Li D, Tian YJ, Guo J, Sun WP, Lun YZ, Guo M, et al.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0165) [Nicotinamide supplementation induces detrimental](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0165) [metabolic and epigenetic changes in developing rats. Br J](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0165) [Nutr 2013;110(12):2156–64.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0165)
6. [Bluher M. Adipose tissue dysfunction in obesity. Exp Clin](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0170) [Endocrinol Diabetes 2009;117:241–50.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0170)
7. [Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C,](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0175) [DeFronzo RA, Mandarino LJ. Paradoxical changes in muscle](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0175) [gene expression in insulin-resistant subjects after sustained](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0175) [reduction in plasma free fatty acid concentration. Diabetes](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0175) [2007;56(3):743–52.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0175)
8. [Vitarius JA. The metabolic syndrome and cardiovascular](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0180) [disease. Mt Sinai J Med 2005;72:257–62.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0180)
9. [Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0185) [Hormonal regulation of adiponectin gene expression in](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0185)

[3T3- L1 adipocytes. Biochem Biophys Res Commun 2002;290:](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0185) [1084–9.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0185)

1. [Turer AT, Scherer PE. Adiponectin: mechanistic insights and](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0190) [clinical implications. Diabetologia 2012;55:2319–26.](http://refhub.elsevier.com/S2314-808X(15)00061-5/sr0190)